Uterine Corpus Sarcoma — Trials

Uterine Corpus Sarcoma — Trials · CancerIndex

Clinical trials

Registered studies

359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 22
Ph III recruiting: 4
Growth YoY: —
Industry share: 15%
Top sponsor: Assistance Publique Hopitaux De Marseille
Termination share: 24.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03493165	Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)	no longer available	—	—	The University of Texas Health Science Center at San AntonioOTHER	0	May 28, 2025	clinicaltrials

Data updated 22 days agoSource updated May 28, 2025source: clinicaltrials